# US 2015/0148524 A1 · Amino acid analogues and methods for their synthesis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0148524 A1
- Document ID: US20150148524A1
- Status: Published application
- Kind: A1
- Application number: 14/409,509
- Filed: 2013-07-08
- Published: 2015-05-28
- Earliest claimed: 2012-07-06
- Assignees: Monash University
- Applicants: Monash University
- Inventors: Zhen Wang; Andrea Robinson; Nicolas Daniel Spiccia; William Roy Jackson
- Web page: https://patentgrep.com/patent/US20150148524A1

## CPC

- C07K 1/006: {of peptides containing derivatised side chain amino acids}
- C07C 269/06: by reactions not involving the formation of carbamate groups
- C07D 255/02: not condensed with other rings
- C07J 9/00: Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J 41/0055: {the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives}
- C07K 2/00: Peptides of undefined number of amino acids; Derivatives thereof
- C07C 2603/18: Fluorenes; Hydrogenated fluorenes
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07J: STEROIDS (seco-steroids C07C)

## Abstract

A method for the synthesis of an amino acid analogue or a salt, solvate, derivative, isomer or tautomer thereof comprising the steps of: (i) subjecting an amino acid containing a metathesisable group to metathesis with a compound containing a complementary metathesisable group of formula (I) or (II): (Formulae (I), (II)) wherein R1 and R2 are independently selected from H and substituted or unsubstituted C1 to C4 alkyl; each R3 is either absent or independently selected from a heteroatom, a substituted or unsubstituted C1 to C20 alkyl, and a substituted or unsubstituted C1 to C20 alkyl group interrupted by one or more heteroatoms; and each X is independently selected from H and an effector molecule; in the presence of a reagent to catalyse the metathesis to form a dicarba bridge between the amino acid containing a metathesisable group and the compound containing a complementary metathesisable group; and (ii) reducing the dicarba bridge to form a saturated dicarba bridge, wherein the reagent used to catalyse step (i) also catalyses step (ii).

## Claims

### Claim 1

A method for the synthesis of an amino acid analogue or a salt, solvate, derivative, isomer or tautomer thereof comprising the steps of:
(i) subjecting an amino acid containing a metathesisable group to metathesis with a compound containing a complementary metathesisable group of formula (I) or (II):
wherein R1 and R2 are independently selected from H and substituted or unsubstituted C1 to C4 alkyl; each R3 is either absent or independently selected from a heteroatom, a substituted or unsubstituted C1 to C20 alkyl, and a substituted or unsubstituted C1 to C20 alkyl group interrupted by one or more heteroatoms; and
each X is independently selected from H and an effector molecule;
in the presence of a reagent to catalyse the metathesis to form a dicarba bridge between the amino acid containing a metathesisable group and the compound containing a complementary metathesisable group; and
(ii) reducing the dicarba bridge to form a saturated dicarba bridge, wherein the reagent used to catalyse step (i) also catalyses step (ii).

### Claim 2 (depends on 1)

The method of claim 1, wherein the metathesisable group of the amino acid is of the general formula (IV):
wherein R4 and R5 are independently selected from H and substituted or unsubstituted C1 to C4 alkyl; and R6 is either absent or selected from a heteroatom, a substituted or unsubstituted C1 to C20 alkyl, and a substituted or unsubstituted C1 to C20 alkyl interrupted by one or more heteroatoms.

### Claim 3 (depends on 1, 2)

The method of claim 1 or 2, wherein the amino acid having the metathesisable group is a compound of formula (VI):
wherein R4 and R5 are independently selected from H and substituted or unsubstituted C1 to C4 alkyl; R6 is either absent or selected from a heteroatom, a substituted or unsubstituted C1 to C20 alkyl, and a substituted or unsubstituted C1 to C20 alkyl interrupted by one or more heteroatoms; Z is selected from H, a salt and a protecting group; and Y is selected from H and a protecting group.

### Claim 4 (depends on 3)

The method of claim 3, wherein the compound of formula (VI) is selected from:
optionally protected allylglycine wherein Z is H or a protecting group, Y is H or a protecting group, R4 and R5 are H, and R6 is absent;
optionally protected crotylglycine wherein Z is H or a protecting group, Y is H or a protecting group, one of R4 and R5 is H and the other is methyl, and R6 is absent; or
optionally protected butenylglycine wherein Z is H or a protecting group, Y is H or a protecting group, R4 and R5 are H, and R6 is methylene.

### Claim 5 (depends on 1, 2, 3)

The method of any one of claims 1 to 3, wherein the heteroatom is selected from group consisting of O, S(O), S(O)2, SO2NH, OS(O2)O, NH, N(R7), PO4, and P(R7)2, wherein each R7 is independently a substituted or unsubstituted C1 to C10 alkyl.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The method of any one of claims 1 to 5, wherein each R3 is the same and each X is the same in the compound of formula (II).

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The method of any one of claims 1 to 6, wherein the amino group of the amino acid containing a metathesisable group is protected during the metathesis reaction.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1 to 7, wherein the reagent used to catalyse step (i) and step (ii) is a ruthenium alkylidene catalyst.

### Claim 9 (depends on 8)

The method of claim 8, wherein the ruthenium alkylidene catalyst is a non-phosphine ruthenium alkylidene catalyst.

### Claim 10 (depends on 9)

The method of claim 9, wherein the non-phosphine ruthenium alkylidene catalyst is a Hoveyda-Grubbs catalyst.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method of any one of claims 1 to 10, wherein the reduction step (ii) is performed at a temperature below 100° C.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The method of any one of claims 1 to 11, wherein the reduction step (ii) is performed at a hydrogen pressure of 100 Psi or less.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The method of any one of claims 1 to 12, wherein the reduction step (ii) is performed in the absence of a base.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The method of any one of claims 1 to 13, wherein the reduction step (ii) is performed in the absence of any further catalyst.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

An amino acid analogue or a salt, solvate, derivative, isomer or tautomer thereof synthesised by the method according to any one of claims 1 to 14.

### Claim 16

A method for preparing a peptide containing an amino acid residue of formula (X1) or a salt, solvate, derivative, isomer or tautomer thereof,
comprising the steps of:
(i) subjecting an amino acid containing a metathesisable group of formula (VI) to metathesis with a compound containing a complementary metathesisable group of formula (I) or (II):
wherein R1, R2, R4 and R5 are independently selected from H and substituted or unsubstituted C1 to C4 alkyl; each R3 is either absent or independently selected from a heteroatom, a substituted or unsubstituted C1 to C20 alkyl, and a substituted or unsubstituted C1 to C20 alkyl group interrupted by one or more heteroatoms; R6 is either absent or selected from a heteroatom, a substituted or unsubstituted C1 to C20 alkyl, and a substituted or unsubstituted C1 to C20 alkyl interrupted by one or more heteroatoms; Z is selected from H, a salt and a protecting group; Y is selected from H and a protecting group; and each X is independently selected from H and an effector molecule;
in the presence of a reagent to catalyse the metathesis to form a dicarba bridge between the amino acid of formula (VI) and the compound of formula (I) or (II);
(ii) reducing the dicarba bridge to form a saturated dicarba bridge, wherein the reagent used to catalyse step (i) also catalyses step (ii); and
(iii) synthesising a peptide by stepwise addition of amino acid residues to produce the peptide, wherein one or more of the amino acid residues is of formula (X1).

### Claim 17 (depends on 16)

A peptide or a salt, solvate, derivative, isomer or tautomer thereof synthesised by the method according to claim 16.

### Claim 18

A method for the synthesis of a peptide or peptides containing a dicarba bridge or a salt, solvate, derivative, isomer or tautomer thereof comprising the steps of:
(i) subjecting a reactable peptide containing a metathesisable group to metathesis with a compound containing a complementary metathesisable group of formula (I′) or (II′):
wherein R1 and R2 are independently selected from H and substituted or unsubstituted C1 to C4 alkyl; each R3 is either absent or independently selected from a heteroatom, a substituted or unsubstituted C1 to C20 alkyl, and a substituted or unsubstituted C1 to C20 alkyl group interrupted by one or more heteroatoms; and each X′ is independently selected from H, an effector molecule, an amino acid and a peptide;
in the presence of a reagent to catalyse the metathesis to form a dicarba bridge between the reactable peptide containing a metathesisable group and the compound containing a complementary metathesisable group; and
(ii) reducing the dicarba bridge to form a saturated dicarba bridge,
wherein the reagent used to catalyse step (i) also catalyses step (ii).

### Claim 19

A method for the synthesis of a peptide containing a dicarba bridge or a salt, solvate, derivative, isomer or tautomer thereof comprising the steps of:
(i) subjecting a reactable peptide containing at least two metathesisable groups to metathesis in the presence of a reagent to catalyse the metathesis to form a dicarba bridge between the metathesisable groups of the reactable peptide; and
(ii) reducing the dicarba bridge to form a saturated dicarba bridge,
wherein the reagent used to catalyse step (i) also catalyses step (ii).

### Claim 20 (depends on 18, 19)

The method of claim 18 or 19, wherein the metathesisable group or groups of the reactable peptide is of the general formula (IV):
wherein R4 and R5 are independently selected from H and substituted or unsubstituted C1 to C4 alkyl; and R6 is either absent or selected from a heteroatom, a substituted or unsubstituted C1 to C20 alkyl, and a substituted or unsubstituted C1 to C20 alkyl interrupted by one or more heteroatoms.

### Claim 21 (depends on 18, 19)

The method of claim 18 or 19, wherein the reactable peptide containing a metathesisable group or groups is a peptide containing at least one compound of formula (VI1):
wherein R4 and R5 are independently selected from H and substituted or unsubstituted C1 to C4 alkyl; R6 is either absent or selected from a heteroatom, a substituted or unsubstituted C1 to C20 alkyl, and a substituted or unsubstituted C1 to C20 alkyl interrupted by one or more heteroatoms; and Z is selected from H, a salt and a protecting group.

### Claim 22 (depends on 21)

The method of claim 21, wherein the compound of formula (VI1) is selected from:
optionally protected allylglycine wherein Z is H or a protecting group, Y is H or a protecting group, R4 and R5 are H, and R6 is absent;
optionally protected crotylglycine wherein Z is H or a protecting group, Y is H or a protecting group, one of R4 and R5 is H and the other is methyl, and R6 is absent; or
optionally protected butenylglycine wherein Z is H or a protecting group, Y is H or a protecting group, R4 and R5 are H, and R6 is methylene.

### Claim 23 (depends on 18)

The method of claim 18, wherein the compound containing a complementary metathesisable group of formula (I) or (II) is a compound of formula (XI) or a peptide containing a compound of formula (XII):
wherein R1 and R2 are independently selected from H and substituted or unsubstituted C1 to C4 alkyl; R3 is either absent or selected from a heteroatom, a substituted or unsubstituted C1 to C20 alkyl, and a substituted or unsubstituted C1 to C20 alkyl interrupted by one or more heteroatoms; Z is selected from H, a salt and a protecting group; and Y is selected from H and a protecting group.

### Claim 24 (depends on 18, 19, 20, 21, 22, 23)

The method of any one of claims 18 to 23, wherein the heteroatom is selected from group consisting of O, S(O), S(O)2, SO2NH, OS(O2)O, NH, N(R7), PO4, and P(R7)2, wherein each R7 is independently a substituted or unsubstituted C1 to C10 alkyl.

### Claim 25 (depends on 18)

The method of claim 18, wherein each R3 is the same and each X′ is the same in the compound of formula (II′).

### Claim 26 (depends on 18, 19, 20, 21, 22, 23, 24, 25)

The method of any one of claims 18 to 25, wherein the amino group of the amino acid containing a metathesisable group is protected during the metathesis reaction.

### Claim 27 (depends on 18, 19, 20, 21, 22, 23, 24, 25, 26)

The method of any one of claims 18 to 26, wherein the reagent used to catalyse step (i) and step (ii) is a ruthenium alkylidene catalyst.

### Claim 28 (depends on 27)

The method of claim 27, wherein the ruthenium alkylidene catalyst is a non-phosphine ruthenium alkylidene catalyst.

### Claim 29 (depends on 28)

The method of claim 28, wherein the non-phosphine ruthenium alkylidene catalyst is a Hoveyda-Grubbs catalyst.

### Claim 30 (depends on 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The method of any one of claims 18 to 29, wherein the reduction step (ii) is performed at a temperature below 100° C.

### Claim 31 (depends on 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The method of any one of claims 18 to 30, wherein the reduction step (ii) is performed at a hydrogen pressure of 100 Psi or less.

### Claim 32 (depends on 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The method of any one of claims 18 to 31, wherein the reduction step (ii) is performed in the absence of a base.

### Claim 33 (depends on 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The method of any one of claims 18 to 32, wherein the reduction step (ii) is performed in the absence of any further catalyst.

### Claim 34 (depends on 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

A peptide or peptides containing a dicarba bridge or a salt, solvate, derivative, isomer or tautomer thereof, synthesised by the method according to any one of claims 18 to 33.
